FBC
PACB icon

Fairfield, Bush & Co’s Pacific Biosciences PACB Stock Holding History

Fairfield, Bush & Co’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,000
Closed -$26.6K – 382
2023
Q2 		$26.6K Buy
+2,000
New +$24.3K 0.01% 253

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Fairfield, Bush & Co's PACB Position: Q3 2023 in Review

Fairfield, Bush & Co sold out of Pacific Biosciences (PACB) in Q3 2023, closing a stake of 2,000 shares — an estimated $26.6K sold.

Fairfield, Bush & Co first reported a position in PACB in Q2 2023 and held it in 1 quarter. The position peaked at $26.6K in Q2 2023. 274 funds tracked by Wall St. Rank hold PACB as of Q3 2023.

  • Fairfield, Bush & Co reported no remaining Pacific Biosciences position as of Q3 2023 after selling out during the quarter.
  • Fairfield, Bush & Co sold 2,000 Pacific Biosciences shares in Q3 2023, an estimated $26.6K.
  • Fairfield, Bush & Co first reported a position in Pacific Biosciences in Q2 2023 and held it in 1 quarter.
  • Fairfield, Bush & Co's Pacific Biosciences position peaked at $26.6K in Q2 2023.
  • 274 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2023.

Based on Fairfield, Bush & Co's 13F filing for Q3 2023, filed 15 Nov 2023.